With fenebrutinib, the company aims to launch a new oral treatment for multiple sclerosis that offers both greater ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when started earlier.

Proteins (evasin) from tick saliva could help treat multiple sclerosis and cancer by suppressing the inflammation and paving the way for new treatments.

An estimated 2.8 million people worldwide are living with multiple sclerosis (MS), according to the National MS Society.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. March is Multiple Sclerosis Awareness Month, a time to ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

Pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). CAMH-led pre-clinical studies using a small molecule drug have shown ...

March is Multiple Sclerosis Awareness Month, a time dedicated to raising awareness about a neurological condition that ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study published in ...

Multiple Sclerosis Awareness Month is a time to recognize those affected by the disease and the treatments available to improve their quality of life.